Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
Table 3
Adverse events.
Grade 1
Grade 2
Grade 3
Grade 4
Hematologic event
Neutropenia#
57 (48.7)#
3 (2.6)#
0 (0.0)#
0 (0.0)#
Febrile neutropenia
0 (0.0)
0 (0.0)
1 (0.9)
0 (0.0)
Anemia
37 (31.6)
14 (12.0)
0 (0.0)
0 (0.0)
Thrombocytopenia
3 (2.6)
3 (2.6)
2 (1.7)
0 (0.0)
Nonhematologic event
Nausea/vomiting
3 (2.6)
0 (0.0)
1 (0.9)
0 (0.0)
Skin
52 (44.4)
17 (14.5)
2 (1.7)
0 (0.0)
Mucositis
9 (7.7)
62 (53.0)
30 (25.6)
3 (2.6)
Xerostomia
3 (2.6)
0 (0.0)
0 (0.0)
0 (0.0)
Anorexia
0 (0.0)
29 (24.8)
6 (5.1)
0 (0.0)
Hyperbilirubinemia*#
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
Acute renal injury
6 (5.1)
1 (0.9)
0 (0.0)
0 (0.0)
Neuropathy#
0 (0.0)#
0 (0.0)#
0 (0.0)#
0 (0.0)#
The definition of hyperbilirubinemia is according to CTCAE v3.0. Grade 1: >ULN-1.5 × ULN; grade 2: >1.5–3.0 × ULN; grade 3: >3.0–10.0 × ULN; and grade 4: >10.0 × ULN.
